Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

156
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
156
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

168
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
168
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

161
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

2.8K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consistent root microbiomes across contrasting habitats in a wild perennial vine.

Plant biology (Stuttgart, Germany)·2026
Same author

Dose optimization of immune checkpoint inhibitors for gastrointestinal malignancies.

ESMO gastrointestinal oncology·2026
Same author

Circulating low-density neutrophils as biomarkers of resistance to first-line anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.

Translational oncology·2026
Same author

<i>MDM2</i> amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry.

ESMO gastrointestinal oncology·2026
Same author

Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry.

ESMO real world data and digital oncology·2026
Same author

Higher rate of pathologic complete response in patients with early-onset locally advanced rectal cancer.

ESMO gastrointestinal oncology·2026

Related Experiment Video

Updated: Apr 26, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.4K

Nab-paclitaxel: a flattering facelift.

A Viúdez1, N Ramírez2, I Hernández-García3

  • 1Department of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Critical Reviews in Oncology/Hematology
|July 23, 2014
PubMed
Summary
This summary is machine-generated.

Nanotechnology enhances cancer treatment by improving drug delivery. Nab-paclitaxel, a nanoparticle albumin-bound paclitaxel, shows improved efficacy in metastatic breast, pancreatic, lung, and melanoma cancers.

Keywords:
Breast cancerNab-paclitaxelNanomedicineNanotechnologyPancreatic cancerSPARC

More Related Videos

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

14.2K
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.6K

Related Experiment Videos

Last Updated: Apr 26, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.4K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

14.2K
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.6K

Area of Science:

  • Oncology
  • Nanomedicine
  • Drug Delivery Systems

Background:

  • Nanotechnology enhances the efficacy and efficiency of cytotoxic chemotherapy agents.
  • Nab-paclitaxel, a nanoparticle albumin-bound paclitaxel, represents a significant advancement in cancer therapy.
  • Conventional paclitaxel faces limitations due to hydrophobicity, impacting its pharmacokinetic and pharmacodynamic profiles.

Purpose of the Study:

  • To evaluate the efficacy of nanotechnology-based drug delivery systems in oncology.
  • To highlight nab-paclitaxel as a paradigm for improved cancer treatment.
  • To explore the potential of nanotechnology in enhancing other cytotoxic agents.

Main Methods:

  • Review of studies on nanotechnology applications in oncology.
  • Analysis of clinical data comparing nab-paclitaxel with conventional paclitaxel therapies.
  • Pharmacokinetic and pharmacodynamic profiling of nanoparticle-drug conjugates.

Main Results:

  • Nab-paclitaxel demonstrates improved pharmacokinetic and pharmacodynamic characteristics compared to conventional paclitaxel.
  • Significant improvements in treatment efficacy were observed in metastatic breast cancer, metastatic pancreatic cancer, stage IIIB-IV non-small cell lung cancer (NSCLC), and metastatic melanoma.
  • Nanoparticle delivery systems neutralize drug hydrophobicity, enhancing therapeutic outcomes.

Conclusions:

  • Nanotechnology, exemplified by nab-paclitaxel, significantly improves cancer treatment efficacy.
  • The application of nanotechnology in drug delivery offers a promising strategy for enhancing the therapeutic potential of existing cytotoxic agents.
  • Further research into nanomedicine holds potential for revolutionizing cancer therapy.